Frontotemporal lobar degeneration remains one of the cruelest diagnostic blind spots in neurology — a group of progressive brain diseases that strip away personality, language, and executive function, often striking adults in midlife, yet lacking the fluid biomarkers that now help clinicians navigate Alzheimer's disease. That gap may be narrowing. A large-scale proteomic study profiling cerebrospinal fluid in genetically characterized FTLD cohorts has identified distinct molecular signatures tied to specific mutations, offering a potential path toward earlier and more precise diagnosis.
Using proximity extension assay technology capable of measuring over 2,900 proteins simultaneously, researchers analyzed CSF from two well-characterized cohorts drawn in part from the GENFI consortium. The discovery cohort included 228 individuals — both symptomatic and presymptomatic carriers of pathogenic variants in C9orf72, GRN, MAPT, and TARDBP genes, alongside healthy non-carriers. A separate validation cohort comprised 164 individuals with clinically diagnosed FTLD-spectrum disorders or intact cognition. Among symptomatic carriers, 23 proteins emerged as significantly dysregulated. Gene Ontology analysis revealed that each genetic subgroup — C9orf72, GRN, and MAPT — carried partially overlapping but meaningfully distinct biological process signatures. Using LASSO regression, the team constructed two diagnostic panels: one distinguishing FTLD-spectrum disorder broadly from controls, and a second targeting individuals with underlying TDP-43 pathology specifically.
The clinical significance of these panels hinges on validation in independent cohorts and, critically, on whether presymptomatic protein shifts prove stable and actionable across diverse populations. The focus on genetic FTLD is both a strength and a limitation — most FTLD cases are sporadic, and it remains unclear how well gene-linked signatures will translate. Still, the scale of protein coverage here is notable; few prior FTLD biomarker studies have approached this proteomic breadth. This work is best characterized as an important discovery-phase advance that will require prospective longitudinal validation before informing clinical practice. If the TDP panel holds up, it could be particularly consequential, given the overlap between TDP-43 pathology and ALS.